- AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as WavePlus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a f…Endpoints · 1mo ago↗ source
- TrumpRx adds hundreds of generic medicines to siteThe Trump administration is significantly building the portfolio of drugs available through its direct-to-consumer platform TrumpRx, adding more than 600 generic medicines. President Donald Trump…Endpoints · 2mo ago↗ source
- Another Paragon offshoot chooses reverse merger, this time for migraine drugsThey say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the…